Your browser doesn't support javascript.
loading
DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
Bernier, Cynthia; Soliman, Ahmed; Gravel, Michel; Dankner, Matthew; Savage, Paul; Petrecca, Kevin; Park, Morag; Siegel, Peter M; Shore, Gordon C; Roulston, Anne.
Afiliação
  • Bernier C; Laboratory for Therapeutic Development.
  • Soliman A; Department of Biochemistry, Rosalind and Morris Goodman Cancer Research Centre.
  • Gravel M; Laboratory for Therapeutic Development.
  • Dankner M; Department of Biochemistry, Rosalind and Morris Goodman Cancer Research Centre.
  • Savage P; Laboratory for Therapeutic Development.
  • Petrecca K; Department of Biochemistry, Rosalind and Morris Goodman Cancer Research Centre.
  • Park M; Department of Biochemistry, Rosalind and Morris Goodman Cancer Research Centre.
  • Siegel PM; Department of Biochemistry, Rosalind and Morris Goodman Cancer Research Centre.
  • Shore GC; Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada.
  • Roulston A; Department of Biochemistry, Rosalind and Morris Goodman Cancer Research Centre.
Anticancer Drugs ; 29(8): 774-785, 2018 09.
Article em En | MEDLINE | ID: mdl-29878901

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Lactamas Macrocíclicas / Antígeno CTLA-4 / Neoplasias de Mama Triplo Negativas / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Lactamas Macrocíclicas / Antígeno CTLA-4 / Neoplasias de Mama Triplo Negativas / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article